Tim Brake
All posts from Tim Brake
Tim Brake in Gainers & Losers,

Shares of Great Basin Scientific, Inc. (NASDAQ:GBSN) lost 76.96% on a 4-week basis

Shares of Great Basin Scientific, Inc. (NASDAQ:GBSN) appreciated by 61% during the past week but lost 76.96% on a 4-week basis. The shares have outperformed the S&P 500 by 63.23% in the past week but underperformed the index by 76.28% in the last 4 weeks.

Great Basin Scientific, Inc. (NASDAQ:GBSN) witnessed a decline in the market cap on Friday as its shares dropped 6.19% or 0.0055 points. After the session commenced at $0.0898, the stock reached the higher end at $0.092 while it hit a low of $0.08. With the volume soaring to 16,694,677 shares, the last trade was called at $0.0834. The company has a 52-week high of $9.08. The company has a market cap of $16 million and there are 190,631,000 shares in outstanding. The 52-week low of the share price is $0.0451.

The Company has disclosed insider buying and selling activities to the Securities Exchange, Spafford David, director of Great Basin Scientific, Inc. had purchased 6,665 shares on August 21, 2015 in a transaction. The price per share was $1.47 and the total amount of the disclosed transaction was $9,798.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices. Institutional Investors own 0.5% of Company shares.

Great Basin Scientific, Inc. is a commercial-stage, molecular diagnostic testing company focused on improving patient care through the development and commercialization of its patented, molecular diagnostic platform designed to test for infectious disease, especially hospital-acquired infections. Its platform includes an analyzer, which it provides for its customers use without charge in the United States, and a diagnostic test, which it sells to its customers. It has two commercially available product, Group B Streptococcus (GBS) test and a diagnostic test for clostridium difficile (C. diff) , which received clearance from the Food and Drug Administration (FDA). As of July 31, 2014, it had 102 customers worldwide (80 in the United States and 22 in the rest of the world), who use an aggregate of 217 analyzers.